Wednesday, 26 August 2026European Markets

ENSURGE MICROPOWER Stock Went Down By Over 23% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of ENSURGE MICROPOWER (Oslo Børs Benchmark Index_GI: ENSU.OL) dropped by a staggering 23.08% in 5 sessions from kr0.33 to kr0.25 at 16:25 EST on Tuesday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is jumping 1.45% to kr1,206.18, after five sequential sessions in a row of losses.

About ENSURGE MICROPOWER

Ensurge Micropower ASA designs, develops, and produces ultrathin energy storage solutions for wearable devices, connected sensors, and other applications. Its solid-state lithium battery technology enables it to produce rechargeable batteries with high energy densities. The company was formerly known as Thin Film Electronics ASA and changed its name to Ensurge Micropower ASA in June 2021. Ensurge Micropower ASA was incorporated in 2005 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, ENSURGE MICROPOWER has a trailing twelve months EPS of kr-0.345.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ENSURGE MICROPOWER's stock is considered to be overbought (>=80).

Volume

Today's last reported volume for ENSURGE MICROPOWER is 1713828 which is 85.34% below its average volume of 5054270.

More news about ENSURGE MICROPOWER (ENSU.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com